Adjuvant Homoeopathic Treatment for Respiratory Sequelae following COVID-19: A Pilot Study
Homœopathic Links · 01.09.2026 · 39 (03) · 147-156
DOI: 10.1055/s-0046-1827486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Homœopathic Links, erschienen am 01.09.2026. Verfasst von Bindu Sharma und 12 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Persistent respiratory symptoms are frequently reported following recovery from COVID-19 infection and may affect pulmonary function, exercise capacity, and quality of life. While supportive therapies are commonly used in clinical practice, evidence regarding integrative approaches such as homoeopathy as an adjunct to conventional management remains limited. To evaluate clinical outcomes of individualized homoeopathic treatment administered as an adjunct to conventional care in patients experiencing respiratory sequelae following COVID-19 infection. A prospective, single-arm, open-label pilot clinical study was conducted from August 2021 to September 2022 at All India Institute of Medical Sciences, New Delhi, India. Participants aged ≥18 years with persistent respiratory symptoms following COVID-19 infection were recruited. Individualized homoeopathic medicines were prescribed as an adjunct to standard conventional management. Clinical outcomes included pulmonary function tests (PFTs), 6-minute walk test (6MWT), Numeric Rating Scale (NRS) for respiratory symptoms, Modified Medical Research Council Dyspnoea Scale (mMRC), and health-related quality of life assessed using EuroQol-5 Dimensions-5 Levels (EQ-5D-5L). Assessments were conducted at baseline and after 3 months of follow-up. Of 162 individuals screened, 62 participants were enrolled and 50, who completed the study analyses demonstrated improvement in forced vital capacity (mean difference: 0.21 ± 0.05), 6-minute walk distance (6MWD; mean difference: 33.64 ± 9.52 meters), and symptom scores assessed using NRS, mMRC, and the EQ-5D-5L domains. Improvements observed in pulmonary function, exercise capacity, and symptom scores should be interpreted cautiously due to the single-arm pilot design. Larger randomized controlled trials with comparator groups are required.
Zitieren
APA
Sharma, B., Chhikara, J., Misra, P., Srivastava, G., Taneja, D., Mittal, S., Sharma, P., Khurana, A., Kaushik, S., Madan, K., Hadda, V., Guleria, R., & Mohan, A. (2026). Adjuvant Homoeopathic Treatment for Respiratory Sequelae following COVID-19: A Pilot Study. Homœopathic Links, 39(03), 147-156. https://doi.org/10.1055/s-0046-1827486
Vancouver
Sharma B, Chhikara J, Misra P, Srivastava G, Taneja D, Mittal S, et al. Adjuvant Homoeopathic Treatment for Respiratory Sequelae following COVID-19: A Pilot Study. Homœopathic Links. 2026;39(03):147-156. doi:10.1055/s-0046-1827486
BibTeX
@article{Sharma2026,
author = {Sharma, Bindu and Chhikara, Jyoti and Misra, Pankhuri and Srivastava, Garima and Taneja, Divya and Mittal, Saurabh and Sharma, Pawan and Khurana, Anil and Kaushik, Subhash and Madan, Karan and Hadda, Vijay and Guleria, Randeep and Mohan, Anant},
title = {Adjuvant Homoeopathic Treatment for Respiratory Sequelae following COVID-19: A Pilot Study},
journal = {Homœopathic Links},
year = {2026},
volume = {39},
number = {03},
pages = {147--156},
doi = {10.1055/s-0046-1827486}
}
EUVIMED